Compare RMD & MDLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMD | MDLN |
|---|---|---|
| Founded | 1989 | 1966 |
| Country | United States | United States |
| Employees | 10600 | 45000 |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.2B | 34.1B |
| IPO Year | N/A | N/A |
| Metric | RMD | MDLN |
|---|---|---|
| Price | $220.06 | $41.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 23 |
| Target Price | ★ $293.70 | $50.48 |
| AVG Volume (30 Days) | 905.2K | ★ 6.2M |
| Earning Date | 04-22-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.58 | $10.83 |
| Revenue Next Year | $7.38 | $7.68 |
| P/E Ratio | ★ $25.61 | $658.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $199.92 | $38.50 |
| 52 Week High | $293.81 | $50.88 |
| Indicator | RMD | MDLN |
|---|---|---|
| Relative Strength Index (RSI) | 25.68 | 38.90 |
| Support Level | N/A | $40.76 |
| Resistance Level | $260.21 | $44.11 |
| Average True Range (ATR) | 5.21 | 1.22 |
| MACD | -1.21 | -0.06 |
| Stochastic Oscillator | 1.59 | 16.87 |
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Medline is the largest medical-surgical products and supply chain solutions provider in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.